Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders
PR Newswire —
Issued on behalf of Helus Pharma VANCOUVER, BC, Feb. 26, 2026 /PRNewswire/ -- USA News Group News Commentary – The first psilocybin compound to achieve two positive Phase 3 results in treatment-resistant depression cleared that milestone this week, signaling a potential shift in how...